Published in Am J Hum Genet on May 01, 1997
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Population genetics of BRCA1 and BRCA2. Am J Hum Genet (1997) 3.28
Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet (2000) 2.77
The 2588G-->C mutation in the ABCR gene is a mild frequent founder mutation in the Western European population and allows the classification of ABCR mutations in patients with Stargardt disease. Am J Hum Genet (1999) 2.20
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
BRCA1 mutations in southern England. Br J Cancer (1998) 1.55
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J (2010) 1.52
A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer (2001) 1.44
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Multiplex SNaPshot for detection of BRCA1/2 common mutations in Spanish and Spanish related breast/ovarian cancer families. BMC Med Genet (2007) 1.19
High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res (2005) 1.19
Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res (2002) 1.02
BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Fam Cancer (2006) 1.00
Founder populations and their uses for breast cancer genetics. Breast Cancer Res (2000) 0.99
Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genet (2012) 0.95
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet (2005) 0.94
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br J Cancer (1999) 0.93
Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br J Cancer (2000) 0.92
High frequency of BRCA1/2 germline mutations in 42 Belgian families with a small number of symptomatic subjects. J Med Genet (1999) 0.92
Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet (2003) 0.90
BRCA1 and BRCA2 mutations in Scotland and Northern Ireland. Br J Cancer (2003) 0.88
BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer (2004) 0.87
Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br J Cancer (2000) 0.87
Ashkenazi Jews and breast cancer: the consequences of linking ethnic identity to genetic disease. Am J Public Health (2006) 0.87
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2008) 0.86
Mutation analysis of BRCA1 gene in African-American patients with breast cancer. J Natl Med Assoc (2000) 0.85
BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. Fam Cancer (2004) 0.83
BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat (2007) 0.81
Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection. J Exp Clin Cancer Res (2010) 0.81
Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands. Am J Hum Genet (1998) 0.79
The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet (2006) 0.79
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features. Br J Cancer (2001) 0.77
Establishing a program for individuals at high risk for breast cancer. J Cancer (2013) 0.75
A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res (1988) 77.80
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature (1986) 17.77
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Mutation of human short tandem repeats. Hum Mol Genet (1993) 14.03
Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1993) 11.01
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nat Genet (1995) 5.11
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet (1996) 4.36
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet (1994) 4.15
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet (1994) 2.66
Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat (1996) 2.54
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet (1995) 2.42
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet (1995) 1.85
The genetics of breast and ovarian cancer. Br J Cancer (1995) 1.78
BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet (1995) 1.75
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet (1996) 1.69
Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics (1994) 1.62
A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet (1996) 1.45
High-density genetic map of the BRCA1 region of chromosome 17q12-q21. Genomics (1993) 1.28
Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet (1996) 1.14
Mutation nomenclature: nicknames, systematic names, and unique identifiers. Hum Mutat (1996) 1.14
A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet (1996) 1.12
The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2. Eur J Hum Genet (1996) 0.91
Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum Genet (1995) 0.88
BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene (1996) 0.86
New Austrian mutation in BRCA1 gene detected in three unrelated HBOC families. Lancet (1996) 0.84
Linkage of early-onset familial breast cancer to chromosome 17q21. Science (1990) 16.21
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Mutations in the p53 gene occur in diverse human tumour types. Nature (1989) 13.62
Use and misuse of population attributable fractions. Am J Public Health (1998) 12.96
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Laminin receptor on platelets is the integrin VLA-6. Nature (1988) 4.91
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 4.26
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
Jefferson fathered slave's last child. Nature (1998) 3.83
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood (1990) 3.65
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
Growth retardation and tumour inhibition by BRCA1. Nat Genet (1996) 3.47
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol (1987) 2.96
A complex of platelet glycoproteins Ic and IIa identified by a rat monoclonal antibody. J Biol Chem (1987) 2.94
Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol (2000) 2.93
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet (2000) 2.84
The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet (1986) 2.78
Poisoning with maprotiline and mianserin. Br Med J (1977) 2.64
Rapid subchromosomal localization of cosmids by nonradioactive in situ hybridization. Cytogenet Cell Genet (1990) 2.60
Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol (2001) 2.57
Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature (1988) 2.47
Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet (1996) 2.36
A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer (2006) 2.33
Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet (1997) 2.27
Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. Am J Epidemiol (1998) 2.27
In situ hybridization as a tool to study numerical chromosome aberrations in solid bladder tumors. Histochemistry (1988) 2.26
Participation rates in a case-control study: the impact of age, race, and race of interviewer. Ann Epidemiol (1999) 2.21
Paracetamol poisoning in children. Br Med J (1978) 2.17
Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes. Mol Biol Rep (1990) 2.12
Excess maternal transmission of type 2 diabetes. The Northern California Kaiser Permanente Diabetes Registry. Diabetes Care (1999) 2.11
Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci (1992) 2.11
Effects of passive immunization on experimental syphilis in the rabbit. Johns Hopkins Med J (1973) 2.07
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 1.99
Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut (2002) 1.96
Two subsets of human alphoid repetitive DNA show distinct preferential localization in the pericentric regions of chromosomes 13, 18, and 21. Cytogenet Cell Genet (1986) 1.90
Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nat Genet (1994) 1.88
Seroconversion for Helicobacter pylori. Lancet (1993) 1.88
Sporadic imprinting defects in Prader-Willi syndrome and Angelman syndrome: implications for imprint-switch models, genetic counseling, and prenatal diagnosis. Am J Hum Genet (1998) 1.87
Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am J Clin Pathol (1996) 1.84
Classification of Fanconi anemia patients by complementation analysis: evidence for a fifth genetic subtype. Blood (1995) 1.82
Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. Oncogene (1991) 1.81
A straightforward approach to isolate DNA sequences with potential linkage to the retinoblastoma locus. Hum Genet (1986) 1.80
A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum Mol Genet (1992) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia (2009) 1.75
Demonstration of a virus-like agent contaminating material containing the Stockholm substrain of the Nichols pathogenic Treponema pallidum. Br J Vener Dis (1970) 1.74
Environmental contaminants and body fat distribution. Cancer Epidemiol Biomarkers Prev (1999) 1.74
Infectivity tests in syphilis. Br J Vener Dis (1969) 1.73
Activation of LFA-1 through a Ca2(+)-dependent epitope stimulates lymphocyte adhesion. J Cell Biol (1991) 1.72
ELFT: a gene that directs the expression of an ELAM-1 ligand. Cell (1990) 1.70
The alpha 6 beta 4 integrin is a receptor for both laminin and kalinin. Exp Cell Res (1994) 1.69
Assignment of a second locus for multiple exostoses to the pericentromeric region of chromosome 11. Hum Mol Genet (1994) 1.68
Area-level characteristics and smoking in women. Am J Public Health (2001) 1.68
Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 1.68
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer (2012) 1.66
Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer (2002) 1.65
Are heavy smokers different from light smokers? A comparison after 48 hours without cigarettes. JAMA (1988) 1.65
Sequence heterogeneity within the human alphoid repetitive DNA family. Nucleic Acids Res (1986) 1.65
Classification of Osteogenesis Imperfecta revisited. Eur J Med Genet (2009) 1.64
Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol (1997) 1.63
COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer (2009) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Eight novel inactivating germ line mutations at the APC gene identified by denaturing gradient gel electrophoresis. Genomics (1992) 1.59
Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology (2003) 1.59
Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol (1997) 1.59
Catechol-O-methyltransferase and breast cancer risk. Carcinogenesis (1998) 1.58
Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol (2000) 1.58
Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet (1996) 1.58
Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat (2004) 1.57
Mental status of females with an FMR1 gene full mutation. Am J Hum Genet (1996) 1.57
Distinct and overlapping ligand specificities of the alpha 3A beta 1 and alpha 6A beta 1 integrins: recognition of laminin isoforms. Mol Biol Cell (1994) 1.56
Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res (2000) 1.55
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer (2005) 1.54
Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis (1992) 1.54
Genetic and behavioral determinants of waist-hip ratio and waist circumference in women twins. Obes Res (1998) 1.53
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Identification and characterization of a novel antigen complex on mouse mammary tumor cells using a monoclonal antibody against platelet glycoprotein Ic. J Biol Chem (1988) 1.51
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer (2000) 1.51